Effects of Duolatopeptide Combined with Probiotics on Glucose and Lipid Metabolism,Islet Function and Cardiovascular Events in Type 2 Diabetic Patients

XU Dandan; TIAN Jinxia; YANG Yanfei; YU Zijuan; SU Haiyan; CAO Wenjuan; WANG Yan

doi:10.3969/j.issn.1002-3429.2024.20.019

Abstract：Objective To observe the effects of duolatopeptide combined with probiotics on glucose and lipid metabo-lism,islet function and cardiovascular events in patients with type 2 diabetic mellitus(T2DM),in order to increase the atten-tion to treatment safety.Methods A total of 120 T2DM patients treated from January 2022 to January 2024 were selected and divided into the observation group(n=60)and the control group(n=60)according to different treatment methods.The con-trol group was given basic treatment combined with Duloglucopeptide therapy,and the observation group was treated with bifidobacterium tetrad viable tablet on the basis of the control group.Both groups were treated for three consecutive months.Fasting blood glucose(FBG),glycated hemoglobin(HbA1c),2 h postprandial blood glucose(2 h PBG)levels and body mass index(BMI)of the two groups after treatment,fasting insulin,islet beta cell function index(HOMA-β)levels and in-sulin resistance index(HOMA-IR)of the two groups before and after treatment were compared,and cardiovascular events of the two groups during treatment were analyzed.In addition,the levels of C reactive protein(CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),total cholesterol(TC),triglyceride(TG)and low-density lipoprotein cholesterol(LDL-C)after treatment in the two groups were compared.Results After treatment,FBG,2 h PBG,HbA1c and BMI in ob-servation group were lower than those in control group(P＜0.05).After treatment,HOMA-β and fasting insulin were in-creased,while fasting HOMA-IR was decreased in the two groups than those before treatment(P＜0.05).After treatment,HOMA-β was higher while HOMA-IR was lower in observation group than in control group(P＜0.05).The total incidence of cardiovascular events in the observation group was lower than that in the control group(P＜0.05).After treatment,IL-6,TNF-α,CRP,TC,TG and LDL-C in observation group were lower than those in control group(P＜0.05).Conclusion Duo-laglycopeptide combined with probiotics can effectively stabilize blood glucose and lipid levels in T2DM patients,improve islet function,control body mass,and reduce inflammatory reaction,thus greatly reducing the incidence of cardiovascular adverse events and improving the safety of drug use.